Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.

Multitarget-directed ligands might offer certain advantages over traditional single-target drugs and/or drug combinations. In the present study, a series of novel analgesic agents targeting both cyclooxygenase and TRPV1 were prepared and evaluated in an effort to optimize properties of previously described lead compounds from piperazine, ethanediamine cores. These compounds were evaluated for antagonism of hTRPV1 activation by capsaicin and the ability to inhibit Ovine COX-1 and human recombinant COX-2 in vitro. The favorable potentials of these test compounds were further characterized in preliminary analgesic and side-effects tests in vivo. On the basis of comprehensive evaluations, compound 8d which showed strong TRPV1 antagonistic activity, middle COX-2 inhibition, weak ulcerogenic action and had no hyperthermia side-effect was considered as a safe candidate for the further development of analgesic drugs.

[1]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Gomtsyan,et al.  Pharmacology of Modality-Specific Transient Receptor Potential Vanilloid-1 Antagonists That Do Not Alter Body Temperature , 2012, Journal of Pharmacology and Experimental Therapeutics.

[3]  J. C. Winter,et al.  Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I₂ receptor ligands. , 2011, European journal of pharmacology.

[4]  M. Cascio,et al.  First “hybrid” ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non‐polyunsaturated fatty acid‐derived CB2‐selective ligands , 2006, FEBS letters.

[5]  K. Tan-No,et al.  Effect of spinal nitric oxide inhibition on capsaicin-induced nociceptive response. , 1996, Life sciences.

[6]  C. Goodchild,et al.  Prospective audit of short‐term concurrent ketamine, opioid and anti‐inflammatory (‘triple‐agent’) therapy for episodes of acute on chronic pain , 2005, Internal medicine journal.

[7]  M. Andresen,et al.  Cannabinoid 1 and Transient Receptor Potential Vanilloid 1 Receptors Discretely Modulate Evoked Glutamate Separately from Spontaneous Glutamate Transmission , 2014, The Journal of Neuroscience.

[8]  Neelima Khairatkar-Joshi,et al.  TRPV1 antagonists: the challenges for therapeutic targeting. , 2009, Trends in molecular medicine.

[9]  E. Nielsen,et al.  Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3′-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  J. Louis,et al.  Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[11]  Kay Brune,et al.  Reversal of pathological pain through specific spinal GABAA receptor subtypes , 2008, Nature.

[12]  E. Romero-Sandoval,et al.  Antinociception and the new COX inhibitors: research approaches and clinical perspectives. , 2006, CNS drug reviews.

[13]  J. Treanor,et al.  The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation , 2007, The Journal of Neuroscience.

[14]  E. Walters,et al.  Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain , 2013, Current neuropharmacology.

[15]  A. Hohmann,et al.  A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation , 2003, Neuroscience.

[16]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Liliana M. Pacureanu,et al.  COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles , 2017, Molecules.

[18]  M. Blanco,et al.  Recent progress in the development of selective TRPV1 antagonists for pain. , 2008, Current topics in medicinal chemistry.

[19]  Michael Koblish,et al.  Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. , 2005, European journal of pharmacology.

[20]  L. Koetzner,et al.  Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy , 2005, Neuropharmacology.

[21]  A. Lichtman,et al.  The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1 , 2009, British journal of pharmacology.

[22]  A. Hohmann,et al.  Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism , 2010, Nature Neuroscience.

[23]  T. Schnitzer,et al.  A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. , 2004, Journal of pain and symptom management.

[24]  Aijun Li,et al.  Enhancement of apamin-sensitive medium afterhyperpolarization current by anandamide and its role in excitability control in cultured hippocampal neurons , 2011, Neuropharmacology.

[25]  J. Reisz,et al.  Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies. , 2011, Journal of medicinal chemistry.

[26]  A. Romano,et al.  The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. , 2009, International review of neurobiology.

[27]  B. C. Tel,et al.  Thiazolo[3,2-b]-1,2,4-triazole-5(6H)-one substituted with ibuprofen: novel non-steroidal anti-inflammatory agents with favorable gastrointestinal tolerance. , 2012, European journal of medicinal chemistry.

[28]  Helen E. Gibson,et al.  A novel non‐CB1/TRPV1 endocannabinoid‐mediated mechanism depresses excitatory synapses on hippocampal CA1 interneurons , 2012, Hippocampus.

[29]  Vincent J. Dupriez,et al.  Adaptation of Aequorin Functional Assay to High Throughput Screening , 2002, Journal of biomolecular screening.

[30]  T. Aoki,et al.  Amelioration of Neuropathic Pain by Novel Transient Receptor Potential Vanilloid 1 Antagonist AS1928370 in Rats without Hyperthermic Effect , 2011, Journal of Pharmacology and Experimental Therapeutics.

[31]  Wen-long Huang,et al.  Evaluation of Anti‐inflammatory and Analgesic Effects of Synthesized Derivatives of Ibuprofen , 2015, Chemical biology & drug design.

[32]  Jun-Xu Li,et al.  Emerging drug targets for pain treatment. , 2012, European journal of pharmacology.

[33]  P. Blumberg,et al.  Antinociceptive Pharmacology of N-(4-Chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl) Thiourea, a High-Affinity Competitive Antagonist of the Transient Receptor Potential Vanilloid 1 Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.

[34]  Moshfiqur Rahman,et al.  Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies. , 2010, Bioorganic & medicinal chemistry letters.

[35]  Susan M Westaway,et al.  The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. , 2007, Journal of medicinal chemistry.

[36]  J. C. Winter,et al.  Effects of imidazoline I₂ receptor ligands on morphine- and tramadol-induced antinociception in rats. , 2011, European journal of pharmacology.

[37]  Angelo D. Favia,et al.  Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. , 2012, Journal of medicinal chemistry.

[38]  Jun-Xu Li,et al.  Imidazoline I2 receptors: target for new analgesics? , 2011, European journal of pharmacology.

[39]  A. Sunshine,et al.  Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine , 2005, Headache.

[40]  T. Vanderah,et al.  CB2 cannabinoid receptor-mediated peripheral antinociception , 2001, Pain.

[41]  V. Di Marzo,et al.  Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. , 2009, Bioorganic & medicinal chemistry letters.